REFLAB ApS
Core data
Name | REFLAB ApS |
Address | Kanalholmen 1 2, 2650, Hvidovre |
Founded | Apr 22, 1991 |
| 10 / 9 | |
Locations (P-units) | 1View locations |
Website | https://reflab.dk/ |
 LinkedIn | reflab-aps |
Branch | Traditionelle, komplementære og alternative behandlingsformer (869600) |
Name | REFLAB ApS |
Address | Kanalholmen 1 2, 2650, Hvidovre |
Founded | Apr 22, 1991 |
| 10 / 9 |
Locations (P-units) | 1View locations |
Website | https://reflab.dk/ |
| LinkedIn | reflab-aps |
Branch | Traditionelle, komplementære og alternative behandlingsformer (869600) |
Keep track of REFLAB ApS
Description
RefLab is a private Danish laboratory specializing in allergy and chronic spontaneous urticaria diagnostics, and operates as a contract research organization offering allergen standardization and human ex vivo models for preclinical research.
RefLab provides clinically relevant allergy and immunology assays, including basophil histamine release testing, and tailored contract research using human ex vivo skin models for therapeutic development.
Company's own description on virk.dk
Selskabets hovedaktivitet består i at drive laboratorievirksomhed ved udførelse af klinisk kemiske analyser, herunder produktion af diagnostiske kits til udførelse af nævnte analyser.
Products & services
Allergen-induced basophil histamine release assay (a-BHRA / HR-Test) · Serum-induced basophil histamine release assay (s-BHRA / HR-Urticaria Test) · Allergy testing, including drug, food, and inhalant allergy · Chronic spontaneous urticaria (CSU) testing · Biological standardization of allergens · Human ex vivo skin model · Ex vivo human skin microdialysis model · Contract research for dermal drug delivery, hypersensitivity reactions, local pharmacodynamic effects, and local metabolism
Industries
Allergy and immunology diagnostics · Contract research organization
Customer types
Hospitals · Allergy/immunology specialists · Private companies · Biotechnology companies · Pharmaceutical companies
Financials
| Reporting period | 2025DKK | |||||||
|---|---|---|---|---|---|---|---|---|
| Gross profit | 4,582,184 | |||||||
| Operating profit | -2,151,498 | |||||||
| Profit before tax | -2,297,656 | |||||||
| Net income | -1,792,430 | |||||||
| Total assets | 4,506,262 | |||||||
| Equity | -635,048 | |||||||
| Avg. employees | 10 | |||||||
2018–2025 Unlock financial history | ||||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
Founders
| Founder | Registered as founder | Current roles | Ownership |
|---|---|---|---|
| Per Stahl Skov | Registered as founderApr 22, 1991 | Current roles — | Ownership — |
People
| Person | Roles | Titles |
|---|---|---|
| Gert Pynt Andersen | Roles Management | TitlesDIREKTØR |
| Katrine Baumann Markussen | Roles Management | TitlesDIREKTØR |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| Baker Tilly Denmark | AuditorHelle Brandt Møller | Rolestatsautoriseret revisor | FromApr 20, 2026 |
| Baker Tilly Denmark | Auditor— | Role— | FromApr 20, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
Foreign legal entity | Ownership100 % | Voting rights100 % | FromJan 1, 2010 |
Beneficial owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
Unknown Other Participant | Ownership20 % | Voting rights53.9 % | FromJan 1, 2010 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇩🇪R-Biopharm AG | Ownership through Direct | 100 % |